Patient-reported outcomes in adults with type 1 diabetes in global real-world clinical practice: The SAGE study.

Autor: Wilmot EG; Diabetes Department, Royal Derby Hospital, Derby, UK.; University of Nottingham, Nottingham, UK., Close KL; The diaTribe Foundation, San Francisco, California, USA., Jurišić-Eržen D; University of Rijeka, Rijeka, Croatia., Bruttomesso D; University of Padova, Padova, Italy., Ampudia-Blasco FJ; Clinic University Hospital, University of Valencia, Valencia, Spain., Bosnyak Z; Sanofi, Paris, France., Roborel de Climens A; Sanofi, Paris, France., Bigot G; Ividata Life Sciences, Levallois-Perret, France., Peters AL; Keck School of Medicine of the University of Southern California, Los Angeles, California, USA., Renard E; Department of Endocrinology, Diabetes, Nutrition, Montpellier University Hospital; INSERM Clinical Investigation Centre 1411; Institute of Functional Genomics, CNRS, INSERM, University of Montpellier, Montpellier, France., Berard L; Nurse Consultant, Winnipeg, Manitoba, Canada., Calliari LE; Santa Casa de Sao Paulo School of Medical Sciences, Sao Paulo, Brazil., Seufert J; Medical Faculty, University Hospital of Freiburg, Freiburg, Germany.
Jazyk: angličtina
Zdroj: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2021 Aug; Vol. 23 (8), pp. 1892-1901. Date of Electronic Publication: 2021 Jun 14.
DOI: 10.1111/dom.14416
Abstrakt: Aims: To conduct a secondary analysis of the SAGE study to evaluate the association between glycaemic control and patient-reported outcomes (PROs), in adults with type 1 diabetes (T1DM) across different age groups and regions.
Materials and Methods: SAGE was a multinational, cross-sectional, observational study in adults with T1DM. Data were collected at a single visit, analysed according to predefined age groups (26-44, 45-64, and ≥65 years), and reported across different regions. PRO questionnaires were applied to assess hypoglycaemia fear (Hypoglycemia Fear Survey-II), diabetes-related distress (Problem Areas In Diabetes questionnaire), insulin treatment satisfaction (Insulin Treatment Satisfaction Questionnaire), and diabetes-specific quality of life (QoL; Audit of Diabetes-Dependent Quality of Life). Multivariable analysis was performed to evaluate the relationship between glycated haemoglobin (HbA1c) target achievement (<7% and individualised targets) with PRO scores.
Results: The PRO scores showed relatively low levels of diabetes-related emotional distress and fear of hypoglycaemia, moderate to high treatment satisfaction, and low diabetes-related impact on QoL. Results were generally comparable across age groups with some regional variability. Achievement of the HbA1c <7% target was associated with less worry about hypoglycaemia, lower diabetes-related emotional distress, higher insulin treatment satisfaction, and higher QoL. Achievement of individualised HbA1c targets was associated with lower diabetes-related emotional distress and higher insulin treatment satisfaction.
Conclusions: Better glycaemic control was most closely associated with low emotional distress due to diabetes and high patient-reported insulin treatment satisfaction.
(© 2021 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: